DBV TECHNOLOGIES
NASDAQ: DBVT (DBV Technologies S.A.)
Kemas kini terakhir: semalam, 7:49PM15.53
-0.75 (-4.61%)
| Penutupan Terdahulu | 16.28 |
| Buka | 16.64 |
| Jumlah Dagangan | 319,143 |
| Purata Dagangan (3B) | 241,126 |
| Modal Pasaran | 919,169,280 |
| Harga / Buku (P/B) | 4.39 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2026 |
| Margin Operasi (TTM) | -3,534.93% |
| EPS Cair (TTM) | -5.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -46.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 251.79% |
| Nisbah Semasa (MRQ) | 0.720 |
| Aliran Tunai Operasi (OCF TTM) | -89.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.08 M |
| Pulangan Atas Aset (ROA TTM) | -72.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -198.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | DBV Technologies S.A. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.38 |
|
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Institusi | 1.81% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vivo Capital, Llc | 31 Mar 2026 | 2,667,569 |
| Artisan Partners Limited Partnership | 31 Mar 2026 | 2,219,386 |
| Patient Square Capital Lp | 31 Mar 2026 | 693,534 |
| Duquesne Family Office Llc | 31 Mar 2026 | 383,363 |
| Atika Capital Management Llc | 31 Mar 2026 | 271,300 |
| Elmind Capital, Lp | 31 Mar 2026 | 265,000 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |